OR10-05 Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency

Background: The Phase 3 fliGHt Trial evaluated children with growth hormone deficiency (GHD) of a broad range of baseline demographics and treatment durations who switched from daily growth hormone (hGH; somatropin) therapy to once-weekly TransCon hGH. TransCon hGH is an investigational long-acting...

Descripción completa

Detalles Bibliográficos
Autores principales: Maniatis, Aristides K, Nadgir, Ulhas, Saenger, Paul, Mick, Gail, Reifschneider, Kent L, Abuzzahab, Mary Jennifer, Deeb, Larry, Fox, Larry A, Woods, Katie A, Peng, Jessica M, Karpf, David B, Shu, Aimee D, Song, Wenjie, Casella, Samuel J, Thornton, Paul S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209171/
http://dx.doi.org/10.1210/jendso/bvaa046.963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209171/
http://dx.doi.org/10.1210/jendso/bvaa046.963

Ejemplares similares